Login to Your Account

High Number Of Dropouts Spoil Oxytrex Phase III Trial

By Aaron Lorenzo

Wednesday, November 23, 2005
Shares in Pain Therapeutics Inc. lost nearly 20% of their value on news that a Phase III study of Oxytrex was inadequate due to patient dropouts, meaning another trial is in order. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription